Press Releases

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (Alpha Cognition “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce the submission of a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for ALPHA-1062, a proprietary, patented, delayed release oral tablet formulation in development for the treatment of mild-to-moderate

Emmes,a global, full-service Contract Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, announces the addition of telehealth capabilities within Advantage eClinical. The new application means any scheduled visit can become virtual with video calls augmented directly through the platform and patients signing in through their existing participant portal. Advantage eClinical is designed to enable a simple, intuitive experience

The bromine market is expected to be valued at US$ 2.53 billion in 2023. The bromine market is expected to reach US$ 4.7 Billion by 2033. The market revenue is likely to continue to expand at a CAGR of 6.3%. Bromine Market Trends and Highlights Bromine is a liquid element that occurs naturally. In agriculture and sanitation, bromine products are used as pesticides, fumigants, and fire retardants. Many citrus-flavored drinks use bromine as an emulsifier as

The newly developed Freeze-Light-Protect syringe label from Schreiner MediPharm is suitable for deep-freeze applications at temperatures far below zero and at the same time offers individual light protection. Consequently, it is particularly well-suited for use with sensitive mRNA-based substances as well as for cell and gene therapies. Schreiner MediPharm is going to present this innovative label for the first time at this year’s PDA Universe of Pre-Filled Syringes and Injection Device

SpineX Inc., a clinical stage bioelectric medtech company, is pleased to announce receipt of funding from the National Institutes of Health (NIH) through the Small Business Innovation Research Awards (SBIR). These funds will go towards completing a pivotal clinical trial to test the efficacy and safety of our proprietary SCiP™ device in children living with Cerebral Palsy (CP). The clinical trial will support efforts to seek approval to market from the US Food and Drug Adminis

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its lentiviral vector (LVV) manufacturing platform, Lentivation™. The platform has the capability to reduce LVV manufacturing timelines for gene and gene-modified cell therapies by up to 60 percent, translating to fewer than seven months compared to traditional manufacturing workflows. Charles River provides viral vector production services ranging from clone construction through good manu

ProBioGen and GeoVax Labs, Inc., a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, announce the signing of a landmark commercial license agreement for ProBioGen's groundbreaking AGE1.CR.pIX® suspension cell line. The agreement will empower GeoVax to enhance the manufacturing capabilities of its entire Modified Vaccinia Ankara (MVA) based vaccine portfolio. ProBioGen's AGE1.CR.pIX suspension cell line is an innovative

Pierre Fabre Laboratories and Vernalis (R&D) Ltd ("Vernalis"), a fully owned subsidiary of HitGen Inc., are pleased to announce a long-term partnership to identify pre-clinical candidates against multiple oncology targets. Under the terms of the agreement, Vernalis will use its expertise to enable drug discovery against an undisclosed portfolio of targets and use fragment and structure-based methods to identify small molecules that modulate their activity. This researc

Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED), today announced the publication of new preclinical data demonstrating linsitinib reduced pathologic bone marrow activity in a mouse model of TED. The data have been published in the peer-review journal Frontiers in Endocrinology. "As TED develops in patients, autoreactive CD4+ T-cells migrate into the bone marrow, indu

Polpharma Biologics, an international biotech company dedicated to the development and manufacturing of biosimilars, today announced that the European Commission (EC) has approved Tyruko® (natalizumab) as the first and only biosimilar for relapsing forms of multiple sclerosis (MS) in Europe. Tyruko® was developed by Polpharma Biologics and will be commercialized by its collaboration partner Sandoz.(1) Tyruko® received marketing authorization in Europe (1) as a single dis